- Quarterly Reports Use Market Intelligence and Competitive Analysis from Thomson Reuters to Highlight Developments in the Global Pharmaceutical Industry
—
PHILADELPHIA and LONDON, January 21PHILADELPHIA and LONDON, January 21 /PRNewswire/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, has announced the availability of three Pharma Matters reports covering the time period July - September 2008. The quarterly Pharma Matters series covers all aspects of the pharmaceutical pipeline, leveraging strategic intelligence and competitive analysis from Thomson Pharma(R), Newport Horizon Premium(TM) and the Thomson Messaging Mapping System(SM).
The Ones to Watch - A Thomson Reuters quarterly review of the latest phase changes in the pharmaceutical pipeline, this report is based on strategic data and analysis from Thomson Pharma, the world's leading pharmaceutical competitive intelligence solution. In the report covering Q3 2008, the top five most promising drugs launched or receiving approval were:
DRUG DISEASE COMPANY Zeftera(TM) Complicated skin and soft Basilea Pharmaceutica tissue infections Firazyr(R) Hereditary angioedema Jerini Bridion(R) Reversal of muscle Schering-Plough relaxants Cleviprex(TM) Perioperative The Medicines Company hypertension Xarelto(R) Venous thromboembolic Bayer/Ortho-McNeil events Pharmaceutical
More analysis, as well as information on drugs entering clinical Phases I, II and III are available in the full report: http://thomsonreuters.com/content/PDF/scientific/pharma/2008totw_q3.pdf.
Movers and Shakers - This report covers the US generics industry using data and analysis from Newport Horizon Premium, the critical product targeting the global business development system. Analysis from the Q3 2008 report includes:
- The pharmaceutical marketplace continued to demonstrate volatility, and the pace of patent challenges showed no sign of slackening in the third quarter of 2008. - During the third quarter of 2008, final approvals were issued on only 77 'A'-rated ANDAs, plummeting down from 142 the quarter before. First-time approvals of generic products by the FDA also dropped from 11 to 8 this quarter. - Seven new products (three combination products and four single active ingredient products) were subjected to paragraph IV challenges for the first time in Q3 2008, identical to the previous quarter. - Indian groups were in first place in terms of ANDA approvals during Q3 2008. Twelve India-based corporations received a total of 17 final ANDA approvals. - In the same time period, 11 US-based companies received a total of 15 approvals, putting the U.S. in second place for this quarter. - Mylan of the U.S. and Boehringer Ingelheim of Germany received the most final ANDA approvals (seven each).
To learn more about companies making their mark on the U.S. generics market, click here to read the full report: http://thomsonreuters.com/content/PDF/scientific/pharma/2008ms_q3.pdf
Who is Making the Biggest Splash? - A Thomson Reuters expert review of the organizations that are helping to shape professional opinions on drugs and therapies, using the unique insights of the Thomson Message Mapping System. In this quarterly review of the scientific literature on drugs and therapies, Thomson Reuters assesses the quantity and quality of the materials published by pharmaceutical companies, research institutions and other non-commercial bodies. The top five of the 15 listed organizations that have made the biggest impact as the leading sources of information on medical research from July - September 2008 are:
1. Novartis 2. Bristol-Meyers Squibb 3. Eli Lilly 4. Pfizer 5. AstraZeneca
To see the complete list, as well as analysis and methodology, click here to read the full report: http://thomsonreuters.com/content/PDF/scientific/pharma/2008wmtbs_q3.pdf
To sign up for the Thomson Reuters Pharma Matters series of publications visit: http://scientific.thomsonreuters.com/forms/matters/
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to thomsonreuters.com.
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
